Organization and Description of Business	6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	ORGANIZATION AND DESCRIPTION OF BUSINESS CareDx, Inc. (“CareDx” or the “Company”), together with its subsidiaries, is a precision medicine company dedicated to advancing care in transplant, specialty oncology, and cell therapy. The Company delivers solutions designed to empower clinicians and improve patient outcomes. The Company’s portfolio spans non-invasive molecular testing, clinical practice management software, AI-powered data and analytics tools, and patient support solutions designed to connect diagnostic insight, clinical workflow, and patient engagement to help improve patient outcomes. The Company’s headquarters are in Brisbane, California. It operates laboratories in California, North Carolina and Massachusetts. It maintains pharmacies in Mississippi, Louisiana, and Georgia. The Company’s commercially available post-transplant testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA (“dd-cfDNA”) solution for kidney transplant patients, AlloMap® Heart, a gene expression profiling solution for heart transplant patients, AlloSure® Heart, a dd-cfDNA solution for heart transplant patients, HeartCare, the combined use of AlloMap Heart and AlloSure Heart, and AlloSure® Lung, a dd-cfDNA solution for lung transplant patients. The Company’s commercially available specialty oncology service is NavDx®, a blood-based test that detects and monitors human papillomavirus (“HPV”)-mediated cancers — including head, neck, and anal cancers — from diagnosis through post-treatment molecular residual disease (“MRD”) surveillance. The Company has initiated several clinical studies to generate data on its existing and planned future testing services. The Company has signed multiple biopharma research partnerships for AlloCell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy. The Company also provides digital and patient solutions, including clinical practice management software, data and analytics tools, and patient support offerings. Sale of Lab Products Business On April 15, 2026, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”) to sell Eurobio the shares of CareDx AB, the Company's wholly-owned Swedish subsidiary, and certain assets related to the Company’s kitted laboratory products business and related software (collectively, the “products business”). The transaction closed on June 30, 2026 and the Company received cash proceeds of approximately $171.7 million, reflecting the base purchase price of $170.0 million, as adjusted for estimated working capital, cash, and other adjustments, subject to finalization of customary post-closing purchase price adjustments, excluding transaction costs. During the three and six months ended June 30, 2026, the Company recognized a gain on sale of lab products business of approximately $113.0 million, measured as the consideration received less the carrying amount of the net assets transferred to Eurobio or otherwise derecognized (including $4.4 million of goodwill allocated to the products business, which reduced the gain on sale), net of transaction costs of approximately $4.8 million. The foreign currency translation adjustment relates to the reclassification adjustment for accumulated foreign currency translation impacts from the sale of the foreign entities and is included in the gain on sale of lab products business. The gain on sale of lab products business is presented within operating expenses in the unaudited condensed consolidated statements of operations. The products business was a component of the Company’s operations. The Company evaluated the sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and concluded that the transaction did not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results. Accordingly, the historical operating results of the products business continue to be reported within continuing operations for all periods presented.

CareDx, Inc. (“CareDx” or the “Company”), together with its subsidiaries, is a precision medicine company dedicated to advancing care in transplant, specialty oncology, and cell therapy. The Company delivers solutions designed to empower clinicians and improve patient outcomes. The Company’s portfolio spans non-invasive molecular testing, clinical practice management software, AI-powered data and analytics tools, and patient support solutions designed to connect diagnostic insight, clinical workflow, and patient engagement to help improve patient outcomes. The Company’s headquarters are in Brisbane, California. It operates laboratories in California, North Carolina and Massachusetts. It maintains pharmacies in Mississippi, Louisiana, and Georgia.

The Company’s commercially available post-transplant testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA (“dd-cfDNA”) solution for kidney transplant patients, AlloMap® Heart, a gene expression profiling solution for heart transplant patients, AlloSure® Heart, a dd-cfDNA solution for heart transplant patients, HeartCare, the combined use of AlloMap Heart and AlloSure Heart, and AlloSure® Lung, a dd-cfDNA solution for lung transplant patients. The Company’s commercially available specialty oncology service is NavDx®, a blood-based test that detects and monitors human papillomavirus (“HPV”)-mediated cancers — including head, neck, and anal cancers — from diagnosis through post-treatment molecular residual disease (“MRD”) surveillance. The Company has initiated several clinical studies to generate data on its existing and planned future testing services. The Company has signed multiple biopharma research partnerships for AlloCell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy. The Company also provides digital and patient solutions, including clinical practice management software, data and analytics tools, and patient support offerings.

On April 15, 2026, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”) to sell Eurobio the shares of CareDx AB, the Company's wholly-owned Swedish subsidiary, and certain assets related to the Company’s kitted laboratory products business and related software (collectively, the “products business”).

The transaction closed on June 30, 2026 and the Company received cash proceeds of approximately $171.7 million, reflecting the base purchase price of $170.0 million, as adjusted for estimated working capital, cash, and other adjustments, subject to finalization of customary post-closing purchase price adjustments, excluding transaction costs. During the three and six months ended June 30, 2026, the Company recognized a gain on sale of lab products business of approximately $113.0 million, measured as the consideration received less the carrying amount of the net assets transferred to Eurobio or otherwise derecognized (including $4.4 million of goodwill allocated to the products business, which reduced the gain on sale), net of transaction costs of approximately $4.8 million. The foreign currency translation adjustment relates to the reclassification adjustment for accumulated foreign currency translation impacts from the sale of the foreign entities and is included in the gain on sale of lab products business. The gain on sale of lab products business is presented within operating expenses in the unaudited condensed consolidated statements of operations.